

Ambledown 2024 benefit updates

Overall Aggregate Increase
9,5%

Current Annual Overall Limit

R 198,660

To be increased on 1 April 2024
as per Regulatory Requirements

Additional procedures
have been included
for LPE



- Tonsillectomies,
- Myringotomies, and
- Adenoidectomies.




One Penalty Co-payment increases
from R13 000 to

R 15,000



**Upgrade to Extended
Cancer Interventions**

Addition of new cancer drug treatments including biological, immunotherapies, and targeted therapies (including small molecule drugs) to complete our coverage and make it one of the most comprehensive in the Gap Cover market.



All Casualty Ward Benefits
to increase from R10,000 to

R 11,000


This is not a medical scheme and the cover is not the same as that of a medical scheme.
This policy is not a substitute for medical scheme membership.

Extended Cancer Intervention drug list



Available therapies

- Biological cancer drugs
- Immunotherapy
- Hormone Therapy
- Targeted Therapy (including Small Molecule Drugs)
- Photodynamic Therapy
- Stem Cell Transplant



Biological Cancer Drugs



NEW

- Kadcyła (ado-trastuzumab emtansine)
- Enhertu
- Venetoclax
- Obinutuzumab
- Rituximab
- Herceptin

EXISTING

- | | | |
|------------|-------------|--------------|
| • Mylotarg | • Alimta | • Mabthera |
| • Nexavar | • Zevalin | • Votrient |
| • Gleevec | • Avastin | • Gemzar |
| • Sprycel | • Erbitux | • Cisplatin |
| • Faslodex | • Sunitinib | • Everolimus |
| • Velcade | • Sutent | |
| • Tarceva | • Fludara | |

This is not a medical scheme and the cover is not the same as that of a medical scheme.
This policy is not a substitute for medical scheme membership.